丁苯酞软胶囊+依达拉奉治疗脑梗死的临床效果评价(1)
[摘要]目的 探讨丁苯酞软胶囊+依达拉奉治疗脑梗死的临床效果。方法 选取2015年12月～2016年7月我院收治的162例脑梗死患者作为研究对象，按照随机综合平衡法将其分为对照组(n=81)和观察组(n=81)。对照组患者采取依达拉奉治疗，观察组患者在对照组的基础上联合丁苯酞软胶囊治疗，比较两组患者的用药效果。结果 两组患者治疗前的各项指标比较，差异无统计学意义(P>0.05)；两组患者治疗后的肢体功能(Fugl-Meyer)评分、日常生活能力评分(Barthel指数)、认知评估量表(MOCA)评分均高于治疗前，脑卒中量表(NIHSS)评分低于治疗前，差異有统计学意义(P<0.05)；观察组患者治疗后的Fugl-Meyer评分、Barthel指数、MOCA评分[(92.6±0.9)、(82.0±1.4)、(23.0±0.6)分]均显著高于对照组[(84.6±0.6)、(72.9±2.0)、(20.2±1.0)分]，NIHSS评分[(11.1±0.9)分]显著低于对照组[(20.4±1.2)分]，差异有统计学意义(P<0.05)。观察组患者的治疗总有效率为95.06%，显著高于对照组的81.48%，差异有统计学意义(P<0.05)。两组患者治疗前的生活质量评分比较，差异无统计学意义(P>0.05)；两组患者治疗后的生活质量评分均高于治疗前，差异有统计学意义(P<0.05)；观察组患者治疗后的生活质量评分显著高于对照组，差异有统计学意义(P<0.05)。结论 对于脑梗死的患者，在采用依达拉奉治疗的基础上，联合丁苯酞软胶囊治疗，疗效显著，可以改善患者的神经、认知、运动功能和生活质量，提高患者的日常生活能力，值得在临床进一步探讨。
[关键词]脑梗死；丁苯酞软胶囊；依达拉奉；临床效果
[中图分类号] R971 [文献标识码] A [文章编号] 1674-4721(2018)8(c)-0121-04
[Abstract] Objective To investigate the clinical effect of Butylphthalide Soft Capsules plus Edaravone in the treatment of cerebral infarction. Methods A total of 162 patients with cerebral infarction who were admitted to our hospital from December 2015 to July 2016 were selected as subjects. They were divided into control group (n=81) and observation group (n=81) according to the random comprehensive balance method. The control group was treated with Edaravone， while in the observation group， Butylphthalide Soft Capsules was added on the basis of the control group .The efficacy of drug use in two groups was compared. Results There was no significant difference between two groups before treatment in indicators (P>0.05). The limb function scores (Fugl-Meyer)， daily living ability scores (Barthel index)， and montreal cognitive assessment (MOCA) scores in two groups after treatment were higher than those before treatment， NIH stroke scale (NIHSS) scores after treatment were lower than those before treatment， and the differences were statistically significant (P<0.05). Fugl-Meyer scores， Barthel index and MOCA scores after treatment in the observation group ([92.6±0.9]， [82.0±1.4]， [23.0±0.6] points) were higher than those in the control group ([84.6±0.6]， [72.9±2.0]， [20.2±1.0] points)， NIHSS scores after treatment in the observation group ([11.1±0.9] points) were lower than those in the control group ([20.4±1.2] points)， and the differences were statistically significant (P<0.05). The total effective rate of the treatment in the observation group was 95.06%， which was significantly higher than that in the control group accounting for 81.48%， and the difference was statistically significant (P<0.05). There was no significant difference in scores of life quality between two groups before treatment (P>0.05). Scores of life quality after treatment in two groups were higher than those before treatment， and the differences were statistically significant (P<0.05). Scores of life quality after treatment in the observation group were significantly higher than those in the control group， and the differences were statistically significant (P<0.05). Conclusion For patients with cerebral infarction， on the basis of Edaravone treatment， combination of Butylphthalide Soft Capsules can obtain a remarkable effect by improving patients′ neurological， cognitive， and motor function as well as the quality of life， and enhance patients′ activity of daily living， which is worthy of further exploration in the clinic., http://www.100md.com(谢江 朱镜春)
[关键词]脑梗死；丁苯酞软胶囊；依达拉奉；临床效果
[中图分类号] R971 [文献标识码] A [文章编号] 1674-4721(2018)8(c)-0121-04
[Abstract] Objective To investigate the clinical effect of Butylphthalide Soft Capsules plus Edaravone in the treatment of cerebral infarction. Methods A total of 162 patients with cerebral infarction who were admitted to our hospital from December 2015 to July 2016 were selected as subjects. They were divided into control group (n=81) and observation group (n=81) according to the random comprehensive balance method. The control group was treated with Edaravone， while in the observation group， Butylphthalide Soft Capsules was added on the basis of the control group .The efficacy of drug use in two groups was compared. Results There was no significant difference between two groups before treatment in indicators (P>0.05). The limb function scores (Fugl-Meyer)， daily living ability scores (Barthel index)， and montreal cognitive assessment (MOCA) scores in two groups after treatment were higher than those before treatment， NIH stroke scale (NIHSS) scores after treatment were lower than those before treatment， and the differences were statistically significant (P<0.05). Fugl-Meyer scores， Barthel index and MOCA scores after treatment in the observation group ([92.6±0.9]， [82.0±1.4]， [23.0±0.6] points) were higher than those in the control group ([84.6±0.6]， [72.9±2.0]， [20.2±1.0] points)， NIHSS scores after treatment in the observation group ([11.1±0.9] points) were lower than those in the control group ([20.4±1.2] points)， and the differences were statistically significant (P<0.05). The total effective rate of the treatment in the observation group was 95.06%， which was significantly higher than that in the control group accounting for 81.48%， and the difference was statistically significant (P<0.05). There was no significant difference in scores of life quality between two groups before treatment (P>0.05). Scores of life quality after treatment in two groups were higher than those before treatment， and the differences were statistically significant (P<0.05). Scores of life quality after treatment in the observation group were significantly higher than those in the control group， and the differences were statistically significant (P<0.05). Conclusion For patients with cerebral infarction， on the basis of Edaravone treatment， combination of Butylphthalide Soft Capsules can obtain a remarkable effect by improving patients′ neurological， cognitive， and motor function as well as the quality of life， and enhance patients′ activity of daily living， which is worthy of further exploration in the clinic., http://www.100md.com(谢江 朱镜春)